EN DE
STOCK COMPARISON

Famon Awal Bros Sedaya vs HCA Healthcare: Fair Value & Quality

Both stocks run through our valuation models. Here is how Famon Awal Bros Sedaya (PRAY) and HCA Healthcare (HCA) compare, as of Aug 10, 2026.

As of Aug 10, 2026, Fair Value Calculator sees HCA Healthcare as the more attractively valued of the two: Famon Awal Bros Sedaya trades at IDR 740 versus a fair value of IDR 257 (-65%), while HCA Healthcare trades at $413 versus $555 (+34%).
Famon Awal Bros Sedaya
PRAY.JK · IDR · Health Care
-65%
upside to fair value
overvalued
PriceIDR 740
Fair ValueIDR 257
Quality46/100
HCA Healthcare
HCA · USD · Health Care
+34%
upside to fair value
undervalued
Price$413
Fair Value$555
Quality70/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Famon Awal Bros SedayaHCA Healthcare
Valuation
50.0×P/E (TTM)12.5×
3.71×P/S (TTM)1.06×
2.96×P/B
18.7×EV/EBITDA7.8×
PEG1.18×
Dividend yield0.8%
Dividend per share$2.94
Profitability
7%Net margin9%
8%Operating margin15%
6%Return on equity136%
3%Return on assets12%
Growth
25%Revenue growth (YoY)4%
17.0%Avg. growth/yr (3Y)7.9%
12.7%Avg. growth/yr (5Y)8.0%
Balance & size
0.44×Debt / equity
$956MMarket cap$81B
expensiveGrowth qualityhealthy

HCA Healthcare leads: 3 to 7 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Famon Awal Bros Sedayaof which business quality 47 · market factors 49 HCA Healthcareof which business quality 66 · market factors 46
ProfitabilityMargins and returns on capital today
31
76
Quality GrowthAre margins and returns improving?
40
61
CashflowEarnings quality: real cash, not paper profit
42
62
Fin. StrengthBalance sheet, leverage, solvency risk
62
39
InvestmentDisciplined investing over empire-building
28
75
Low VolatilityCalm price path (market factor)
67
59
MomentumPrice trend over the last 3–12 months (market factor)
37
38
52W MomentumDistance to the 52-week high (market factor)
51
44
Net IssuanceBuybacks instead of dilution
82
100

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Famon Awal Bros Sedaya

Earnings-BasedIDR 222
Dividend DiscountIDR 137
MultiplesIDR 260
Asset-BasedIDR 155
Economic ProfitIDR 149
Growth EarningsIDR 332

16 of 16 models see the stock below the current price.

HCA Healthcare

DCF Models$546
Earnings-Based$289
Dividend Discount$53.85
Multiples$673
Growth DCF$540
Economic Profit$419
Growth Earnings$506

6 of 23 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Famon Awal Bros Sedaya
Bear IDR 193Fair Value IDR 257Bull IDR 322
IDR 740 = current price (white tick)
HCA Healthcare
Bear $270Fair Value $555Bull $841
$413 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Famon Awal Bros Sedaya · Health Care

Quality score46 · below median
Fair value upside-65% · bottom 25%

HCA Healthcare · Health Care

Quality score70 · Top 25%
Fair value upside+34% · Top 25%

Bottom line

As of Aug 10, 2026, Fair Value Calculator sees HCA Healthcare as the more attractively valued of the two: Famon Awal Bros Sedaya trades at IDR 740 versus a fair value of IDR 257 (-65%), while HCA Healthcare trades at $413 versus $555 (+34%).

HCA Healthcare has the higher quality score (70/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.